West Branch Capital LLC Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

West Branch Capital LLC decreased its holdings in Johnson & Johnson (NYSE:JNJFree Report) by 5.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 23,534 shares of the company’s stock after selling 1,356 shares during the quarter. Johnson & Johnson makes up about 1.1% of West Branch Capital LLC’s holdings, making the stock its 21st biggest holding. West Branch Capital LLC’s holdings in Johnson & Johnson were worth $3,404,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in JNJ. Corepath Wealth Partners LLC grew its stake in Johnson & Johnson by 3.7% in the 4th quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company’s stock worth $287,000 after acquiring an additional 70 shares in the last quarter. Bourne Lent Asset Management Inc. grew its stake in Johnson & Johnson by 1.4% in the fourth quarter. Bourne Lent Asset Management Inc. now owns 14,366 shares of the company’s stock worth $2,078,000 after purchasing an additional 200 shares in the last quarter. XML Financial LLC raised its position in Johnson & Johnson by 0.6% during the 4th quarter. XML Financial LLC now owns 69,537 shares of the company’s stock valued at $10,057,000 after purchasing an additional 420 shares in the last quarter. Genesis Private Wealth LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth $308,000. Finally, Red Spruce Capital LLC grew its position in shares of Johnson & Johnson by 5.3% during the 4th quarter. Red Spruce Capital LLC now owns 12,161 shares of the company’s stock worth $1,759,000 after buying an additional 617 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on JNJ. Stifel Nicolaus dropped their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday. Wolfe Research began coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. Royal Bank of Canada restated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Thursday. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Raymond James reduced their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $170.06.

Get Our Latest Stock Report on JNJ

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.1 %

Shares of NYSE:JNJ opened at $146.76 on Friday. The business has a 50-day moving average price of $147.99 and a 200-day moving average price of $155.98. The stock has a market cap of $353.34 billion, a price-to-earnings ratio of 22.07, a PEG ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22,438,500 billion. During the same period in the previous year, the business posted $2.29 EPS. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. Equities analysts predict that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.38%. Johnson & Johnson’s payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.